Carrelizumab
GXL-004
Unknown small_molecule active
Quick answer
Carrelizumab for Esophageal Squamous Cell Carcinoma is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Esophageal Squamous Cell Carcinoma
- Phase
- Unknown
- Modality
- small_molecule
- Status
- active